Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Excited-State Half-Lives in ^{130}Cd and the Isospin Dependence of Effective Charges.

Physical review letters·2024
Same author

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Appropriateness of Antibiotic Prescription During Teleconsultation.

Studies in health technology and informatics·2022
Same author

The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

[Radiation-oncology horizon 2030: From microbiota to plasma laser].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2020
Same journal

White paper on radiotherapy in France: Ten objectives to strengthen one of the major modalities of cancer treatment.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Contemporary survival outcomes of patients with isolated nodal recurrences of breast cancer: A population-based study.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Factors affecting the stability of deep inspiration breath-holding in radiotherapy for left-sided breast cancers.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Incidence and outcomes of radiation-induced sarcomas following radiotherapy for low-grade non-Hodgkin lymphomas: A population-based study.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Radiotherapy as a curative strategy for primary pleural indolent lymphomas: Analytical guidelines based on literature and an illustrative population-based case series.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Cone-beam computed tomography-based radiomics for tumour regression assessment during radiotherapy of non-small-cell lung cancer.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

[Hodgkin's Lymphoma].

F Drouet1, X Cahu, Y Pointreau

  • 1Service de radiothérapie du Centre René-Gauducheau, CRLCC Nantes-Atlantiques, Boulevard Jacques-Monod, 44805 Saint-Herblain cedex, France.

Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|December 7, 2010
PubMed
Summary
This summary is machine-generated.

Hodgkin's lymphoma (HL) management has evolved, with radiotherapy remaining crucial. Current treatments offer high cure rates but require monitoring for delayed side effects like cardiovascular events and secondary cancers.

Related Experiment Videos

Last Updated: Jun 6, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Area of Science:

  • Oncology
  • Radiation Oncology

Context:

  • Hodgkin's lymphoma (HL) accounts for 10-15% of lymphoma cases in France.
  • HL management has significantly improved, achieving cure rates of 75-80% for all stages and up to 90% for early stages.

Purpose:

  • To clarify the epidemiological, radio-anatomical, and prognostic characteristics of HL.
  • To detail practical radiotherapy modalities for HL treatment, including a clinical case.

Summary:

  • Radiotherapy, initially extensive, is now integrated into combined modality therapies for early-stage HL and remains an option for advanced or recurrent disease.
  • The "Involved Field" irradiation is the standard, with new techniques emerging to minimize irradiated tissue and reduce long-term complications.
  • Long-term patient monitoring is essential due to risks of cardiovascular events and secondary cancers.

Impact:

  • Improved understanding of HL radiotherapy applications.
  • Guidance on optimizing treatment strategies to balance efficacy and minimize delayed side effects.
  • Emphasis on the importance of continued research into novel irradiation techniques for HL.